Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gary S. Gordon"'
Autor:
Sebastian Böttcher, Ahmed Salem, Su Young Kim, Stephan Stilgenbauer, Matthew S. Davids, Michael Hallek, Stephen P. Mulligan, Sarit Assouline, Clemens-Martin Wendtner, John F. Seymour, Peter Hillmen, Brenda Chyla, Jennifer Arzt, Johannes Bloehdorn, Lang Zhou, Gary S. Gordon, Johannes Schetelig, Andrew W. Roberts, Anna Schuh, Wojciech Jurczak, Steven Coutre, Talha Munir, Maria Verdugo, Monali Desai, Barbara Eichhorst, William G. Wierda
Publikováno v:
Journal of Clinical Oncology. 36:1973-1980
Purpose Venetoclax is an orally bioavailable B-cell lymphoma 2 inhibitor. US Food and Drug Administration and European Medicines Agency approval for patients with 17p deleted relapsed/refractory chronic lymphocytic leukemia [del(17p) CLL] was based o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34fe2e81a03b393adc753072ea75a91f
https://doi.org/10.1200/jco.2017.76.6840
https://doi.org/10.1200/jco.2017.76.6840
Autor:
Stanislav Spelda, Andrew Coates, Barry L. Dowell, Andrew Krivoshik, Jane Qian, Peter Ansell, Xiangdong Zhou, Gary S. Gordon, Rajendra S. Pradhan, Ann M. Mauer, Martin Šmakal, Evelyn McKeegan, Rosalyn A. Juergens, Charles M. Rudin, Michael S. Wertheim
Publikováno v:
Journal of Clinical Oncology. 29:1075-1082
Purpose ABT-751 is an antimitotic and vascular disrupting agent with potent preclinical anticancer activity. We conducted a phase I and randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in patients with recurrent advanced o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92882bc9bc37b39ddf5c47974e8889d2
https://doi.org/10.1200/jco.2010.32.5944
https://doi.org/10.1200/jco.2010.32.5944
Autor:
Philip C. Hoffman, Stuart A. Krauss, Everett E. Vokes, Harvey M. Golomb, Ann M. Mauer, Rose Arrieta, S. Watson, Charles M. Rudin, Gary S. Gordon
Publikováno v:
Investigational New Drugs. 19:329-333
In a previous phase II trial of the synthetic topoisomerase I inhibitor, 9-aminocamptothecin (9-AC), given as a 72-h infusion, we identified modest single agent activity of 9% in patients with previously untreated advanced non-small cell lung cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::133fc94666468d88b3979e5974bc90a2
https://doi.org/10.1023/a:1010674113243
https://doi.org/10.1023/a:1010674113243
Autor:
Stuart A. Krauss, Harvey M. Golomb, Everett E. Vokes, Ann M. Mauer, Livia Szeto, Philip C. Hoffman, Charles M. Rudin, Gary S. Gordon
Publikováno v:
Clinical lung cancer. 2(2)
STEALTH® cisplatin (SPI-77) is a liposomal formulation of cisplatin that has activity in animal models of non– small-cell lung cancer (NSCLC). Vinorelbine has documented clinical activity in NSCLC. The purpose of this study was to determine the do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::860e0a39115d9b4800f349d25b40e7ac
https://pubmed.ncbi.nlm.nih.gov/14731323
https://pubmed.ncbi.nlm.nih.gov/14731323
Autor:
Charles M. Rudin, Gary S. Gordon, Susie Lee, Everett E. Vokes, Stuart A. Krauss, S. Watson, Chaiyut Charoentum, Ann M. Mauer, Philip C. Hoffman
Publikováno v:
Clinical lung cancer. 3(4)
We performed a study to determine the feasibility of a rapidly alternating administration of cisplatin/vinorelbine (CV) and docetaxel/gemcitabine (DG) in the treatment of advanced non-small-cell lung cancer (NSCLC). Thirty-four patients with NSCLC (6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c242101ca1e99b2db2928714bcb03b5
https://pubmed.ncbi.nlm.nih.gov/14662035
https://pubmed.ncbi.nlm.nih.gov/14662035